JPRN-UMIN000003835已完成2 期
FT monotherapy as adjuvant chemotherapy for HER2 negative breast cancer patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy: Phase 2 study. - UFT monotherapy for non-pCR patients treated with neoadjuvant chemotherapy.
Osaka Medical College Hospital0 个研究点目标入组 50 人开始时间: 2010年7月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Necessary for adjuvant chemotherapies other than UFT. 2. Treated with oral 5-FU agents previously. 3. Pregnant or breastfeeding. 4. Willing for or possibilities of pregnancy. 5. Recieved the organ transplantation previously. 6. Hypersensitive or underwent severe adverse reactions to fluoropyrimidine. 7. Suffered from serious complications. 8. Having fever or possibility of the infection. 9. Metastatic breast cancer. 10. Having past history or treatment of epilepsy, central nurve system disorder, or psychiatric disease. 11. Difficulty with taking oral drugs or upper gastrointestinal function, or malabsorption syndrome. 12. Judged to be ineligible by the investigators.
研究者
相似试验
招募中
1 期
eoadjuvant Chemotherapy for HER2-positive Stage IV advanced gastric cancer with S-1/Cisplatin/TrastuzumabGastric CancerJPRN-UMIN000005548The University of Tokyo Hospital6
尚未招募
不适用
De-escalation of adjuvant chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer subjects who achieved pathological complete response after neoadjuvant chemotherapy and dual HER2-blockadeKCT0007645Korean Cancer Study Group1,065
进行中（未招募）
1 期
Clinical study to test a new treatment regimen without chemotherapy after surgery for patients with early breast cancer that is ‘HER2-positive’ and ‘hormone receptor-negative’, who respond well to a simplified pre-surgery treatment.HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancerEUCTR2020-002918-41-ITInstitut Jules Bordet1,065
尚未招募
不适用
Efficacy analysis of anti-HER2 treatment in HER2-enriched early breast cancer identified by PAM50KCT0006154Yonsei University Health System, Gangnam Severance Hospital59
进行中（未招募）
1 期
PREDIX HER2 - preoperative treatment of HER2 positive breast cancerPrimary breast cancerMedDRA version: 20.0Level: PTClassification code: 10006201Term: Breast cancer stage III Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10006188Term: Breast cancer female NOS Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10006200Term: Breast cancer stage II Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10006191Term: Breast cancer male NOS Class: 10029104CTIS2023-508411-23-00Karolinska University Hospital200